Researchers at Texas A&M University have developed a nasal spray that reversed age-related brain inflammation and improved memory in preclinical models.
The spray delivers extracellular vesicles carrying microRNAs, which reduce inflammation and restore cellular energy, with effects lasting several months after just two doses.
The findings suggest a potential new approach to treating neurodegenerative diseases, with hopes of translating this therapy into human clinical use in the future.
Could a simple nasal spray truly reverse memory loss and brain fog in aging humans, or are the results limited to animal models?
What challenges remain before this nasal spray could be safely tested and approved for use in people with dementia or Alzheimer’s?
How does this research compare to other recent advances in neurodegeneration, such as immune cell therapies or mitochondrial manipulation?
Could similar extracellular vesicle-based therapies eventually be used to treat other neurodegenerative or systemic diseases beyond the brain?
What ethical questions arise if cognitive decline can be reversed—could this redefine what it means to age or be ‘normal’?
How do extracellular vesicles carrying microRNAs bypass the blood-brain barrier, and what might this mean for future drug delivery?
Nasal Spray Using Neural Stem Cell-Derived Extracellular Vesicles Reverses Brain Aging and Delays Alzheimer's Onset by 10-15 Years
Overview
In April 2026, researchers at Texas A&M developed a groundbreaking nasal spray therapy using neural stem cell-derived extracellular vesicles (EVs) to reverse brain aging and Alzheimer's disease in animal models. Delivered intranasally, these EVs bypass the blood-brain barrier to calm harmful brain inflammation, clear toxic protein buildup, and promote new neuron growth. This multi-action approach rapidly improves cognition and sustains benefits with infrequent dosing, potentially delaying Alzheimer's onset by over a decade. The therapy's noninvasive delivery and broad potential applications mark a paradigm shift in treating neurodegeneration, with human trials expected by 2027-2028 amid ongoing efforts to overcome manufacturing and regulatory challenges.